Publications by authors named "Roberto Carlesi"

Claim this Profile
A
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
Juan W Valle, Arndt Vogel, Crystal S Denlinger, Aiwu Ruth He, Li-Yuan Bai, Roberto Carlesi

Lancet Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer.
Stefano Cascinu, György Bodoky, Kei Muro, Eric Van Cutsem, Sang Cheul Oh, Roberto Carlesi

Oncologist· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Linking the Declarations of Helsinki and of Taipei: Critical Challenges of Future-Oriented Research Ethics.
Chieko Kurihara, Varvara Baroutsou, Sander Becker, Johan Brun, Brigitte Franke-Bray, Roberto Carlesi

Front Pharmacol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Use of Gene Therapy Orphan Drugs-Ethical Needs for a Broader Cooperation Between the Pharmaceutical Industry and Society.
Sandor Kerpel-Fronius, Varvara Baroutsou, Sander Becker, Roberto Carlesi, Luis Collia

Front Med (Lausanne)· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings.
Mansoor Saleh, Philippe A Cassier, Lauriane Eberst, Gurudatta Naik, Van K Morris, Roberto M Carlesi

Oncologist· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Linking the Declarations of Helsinki and of Taipei: Critical Challenges of Future-Oriented Research Ethics.
Chieko Kurihara, Varvara Baroutsou, Sander Becker, Johan Brun, Brigitte Franke-Bray, Roberto Carlesi

Front Pharmacol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Charles S Fuchs, Kohei Shitara, Maria Di Bartolomeo, Sara Lonardi, Salah-Eddin Al-Batran, Roberto Carlesi

Lancet Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Spontaneous rectus sheath hematoma as a complication of anticoagulant and antiplatelet therapy: a case report.].
Roberto Maria Carlesi, Maria Chiara Castoldi, Antonio Gaetano Rampoldi, Cristoforo Incorvaia, Paola Centeleghe

Recenti Prog Med· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Shared Ethical Responsibility of Medically and Non-medically Qualified Experts in Human Drug Development Teams.
Sandor Kerpel-Fronius, Sander Becker, Jane Barrett, Johan Brun, Roberto Carlesi

Front Pharmacol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.
Li-Tzong Chen, Do-Youn Oh, Min-Hee Ryu, Kun-Huei Yeh, Winnie Yeo, Roberto Carlesi

Cancer Res Treat· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer.
Kei Muro, Sang Cheul Oh, Yasuhiro Shimada, Keun-Wook Lee, Chia-Jui Yen, Roberto Carlesi

J Gastroenterol Hepatol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Hansjochen Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, György Bodoky, Roberto Carlesi

Lancet Oncol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis